{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:50Z","timestamp":1792783130378,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Fujian Province","award":["2023J011467"],"award-info":[{"award-number":["2023J011467"]}]},{"name":"Natural Science Foundation of Fujian Province","award":["2024J011217"],"award-info":[{"award-number":["2024J011217"]}]},{"name":"National Natural Science Foundation of China","award":["32470612"],"award-info":[{"award-number":["32470612"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Joint Funds for the innovation of science and Technology, Fujian province","award":["2023Y9268"],"award-info":[{"award-number":["2023Y9268"]}]},{"name":"Medical Innovation Project of the Fujian Provincial Health Commission Science and Technology Program","award":["2025CXA053"],"award-info":[{"award-number":["2025CXA053"]}]},{"name":"Medical Innovation Project of the Fujian Provincial Health Commission Science and Technology Program","award":["2023CXA050"],"award-info":[{"award-number":["2023CXA050"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"DOI":"10.1007\/s11010-026-05650-7","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T08:31:06Z","timestamp":1784881866000},"page":"4289-4301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["p53-R280S mutation confers lenvatinib resistance in hepatocellular carcinoma via Bcl-2-mediated anti-apoptotic signaling"],"prefix":"10.1007","volume":"481","author":[{"given":"Niangmei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leijie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"5650_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"5650_CR2","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A (2019) Hepatocellular carcinoma. N Engl J Med 380:1450\u20131462. https:\/\/doi.org\/10.1056\/NEJMra1713263","journal-title":"N Engl J Med"},{"key":"5650_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s44197-023-00109-0","volume":"13","author":"G Cao","year":"2023","unstructured":"Cao G, Liu J, Liu M (2023) Global, regional, and national trends in incidence and mortality of primary liver cancer and its underlying etiologies from 1990 to 2019: results from the global burden of disease study 2019. J Epidemiol Glob Health 13:344\u2013360. https:\/\/doi.org\/10.1007\/s44197-023-00109-0","journal-title":"J Epidemiol Glob Health"},{"key":"5650_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ph14010036","author":"T Hatanaka","year":"2021","unstructured":"Hatanaka T, Naganuma A, Kakizaki S (2021) Lenvatinib for hepatocellular carcinoma: a literature review. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph14010036","journal-title":"Pharmaceuticals (Basel)"},{"key":"5650_CR5","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ (2019) Lenvatinib: a review in hepatocellular carcinoma. Drugs 79:665\u2013674. https:\/\/doi.org\/10.1007\/s40265-019-01116-x","journal-title":"Drugs"},{"key":"5650_CR6","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/mc.23625","volume":"62","author":"A Buttell","year":"2023","unstructured":"Buttell A, Qiu W (2023) The action and resistance mechanisms of Lenvatinib in liver cancer. Mol Carcinog 62:1918\u20131934. https:\/\/doi.org\/10.1002\/mc.23625","journal-title":"Mol Carcinog"},{"key":"5650_CR7","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"key":"5650_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G (2019) Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26:199\u2013212. https:\/\/doi.org\/10.1038\/s41418-018-0246-9","journal-title":"Cell Death Differ"},{"key":"5650_CR9","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/s43018-024-00796-z","volume":"5","author":"G Efe","year":"2024","unstructured":"Efe G, Rustgi AK, Prives C (2024) P53 at the crossroads of tumor immunity. Nat Cancer 5:983\u2013995. https:\/\/doi.org\/10.1038\/s43018-024-00796-z","journal-title":"Nat Cancer"},{"key":"5650_CR10","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","volume":"26","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157\u20132165. https:\/\/doi.org\/10.1038\/sj.onc.1210302","journal-title":"Oncogene"},{"key":"5650_CR11","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2:a001008. https:\/\/doi.org\/10.1101\/cshperspect.a001008","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5650_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030512","author":"K Voskarides","year":"2023","unstructured":"Voskarides K, Giannopoulou N (2023) The role of TP53 in adaptation and evolution. Cells. https:\/\/doi.org\/10.3390\/cells12030512","journal-title":"Cells"},{"key":"5650_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y (2023) Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther 8:92. https:\/\/doi.org\/10.1038\/s41392-023-01347-1","journal-title":"Signal Transduct Target Ther"},{"key":"5650_CR14","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1111\/1759-7714.15044","volume":"14","author":"K Ito","year":"2023","unstructured":"Ito K, Nishio M, Fujiwara K, Nishii Y, Ushiro K, Yasui H, Hataji O (2023) Refractory response to entrectinib for ROS-1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report. Thorac Cancer 14:2622\u20132626. https:\/\/doi.org\/10.1111\/1759-7714.15044","journal-title":"Thorac Cancer"},{"key":"5650_CR15","doi-asserted-by":"publisher","first-page":"e1826","DOI":"10.1038\/cddis.2015.191","volume":"6","author":"BS Tan","year":"2015","unstructured":"Tan BS, Tiong KH, Choo HL, Chung FF, Hii LW, Tan SH, Yap IK, Pani S, Khor NT, Wong SF, Rosli R, Cheong SK, Leong CO (2015) Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF). Cell Death Dis 6:e1826. https:\/\/doi.org\/10.1038\/cddis.2015.191","journal-title":"Cell Death Dis"},{"key":"5650_CR16","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s43018-023-00532-z","volume":"4","author":"Z Su","year":"2023","unstructured":"Su Z, Kon N, Yi J, Zhao H, Zhang W, Tang Q, Li H, Kobayashi H, Li Z, Duan S, Liu Y, Olive KP, Zhang Z, Honig B, Manfredi JJ, Rustgi AK, Gu W (2023) Specific regulation of BACH1 by the hotspot mutant p53(R175H) reveals a distinct gain-of-function mechanism. Nat Cancer 4:564\u2013581. https:\/\/doi.org\/10.1038\/s43018-023-00532-z","journal-title":"Nat Cancer"},{"key":"5650_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9155","volume":"15","author":"H Song","year":"2023","unstructured":"Song H, Wu J, Tang Y, Dai Y, Xiang X, Li Y, Wu L, Wu J, Liang Y, Xing Y, Yan N, Li Y, Wang Z, Xiao S, Li J, Zheng D, Chen X, Fang H, Ye C, Ma Y, Wu Y, Wu W, Li J, Zhang S, Lu M (2023) Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties. Sci Transl Med 15:eabn9155. https:\/\/doi.org\/10.1126\/scitranslmed.abn9155","journal-title":"Sci Transl Med"},{"key":"5650_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13046-025-03386-8","volume":"44","author":"B Zhao","year":"2025","unstructured":"Zhao B, Zhou Y, Cheng N, Zheng X, Chen G, Qi X, Zhang X, Wang F, Zhuang Q, Assaraf YG, Liu X, Wang Y, Zeng Y (2025) Targeted inhibition of PDGFRA with avapritinib, markedly enhances lenvatinib efficacy in hepatocellular carcinoma in vitro and in vivo: clinical implications. J Exp Clin Cancer Res 44:139. https:\/\/doi.org\/10.1186\/s13046-025-03386-8","journal-title":"J Exp Clin Cancer Res"},{"key":"5650_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12609","volume":"7","author":"J Jung","year":"2016","unstructured":"Jung J, Lee JS, Dickson MA, Schwartz GK, Le Cesne A, Varga A, Bahleda R, Wagner AJ, Choy E, de Jonge MJ, Light M, Rowley S, Mace S, Watters J (2016) TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma. Nat Commun 7:12609. https:\/\/doi.org\/10.1038\/ncomms12609","journal-title":"Nat Commun"},{"key":"5650_CR20","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s10495-024-01967-0","volume":"29","author":"X Liu","year":"2024","unstructured":"Liu X, Gao X, Yang Y, Yang D, Guo Q, Li L, Liu S, Cong W, Lu S, Hou L, Wang B, Li N (2024) EVA1A reverses lenvatinib resistance in hepatocellular carcinoma through regulating PI3K\/AKT\/p53 signaling axis. Apoptosis 29:1161\u20131184. https:\/\/doi.org\/10.1007\/s10495-024-01967-0","journal-title":"Apoptosis"},{"issue":"1","key":"5650_CR21","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1038\/s41467-023-40087-2","volume":"14","author":"H Wei","year":"2023","unstructured":"Wei H, Wang H, Wang G, Qu L, Jiang L, Dai S, Chen X, Zhang Y, Chen Z, Li Y, Guo M, Chen Y (2023) Structures of p53\/BCL-2 complex suggest a mechanism for p53 to antagonize BCL-2 activity. Nat Commun 14:4300. https:\/\/doi.org\/10.1038\/s41467-023-40087-2","journal-title":"Nat Commun"},{"key":"5650_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cells12040612","author":"K Miyazaki","year":"2023","unstructured":"Miyazaki K, Morine Y, Xu C, Nakasu C, Wada Y, Teraoku H, Yamada S, Saito Y, Ikemoto T, Shimada M, Goel A (2023) Curcumin-mediated resistance to lenvatinib via EGFR signaling pathway in hepatocellular carcinoma. Cells. https:\/\/doi.org\/10.3390\/cells12040612","journal-title":"Cells"},{"key":"5650_CR23","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1111\/liv.15953","volume":"44","author":"Y Qin","year":"2024","unstructured":"Qin Y, Han S, Yu Y, Qi D, Ran M, Yang M, Liu Y, Li Y, Lu L, Liu Y, Li Y (2024) Lenvatinib in hepatocellular carcinoma: resistance mechanisms and strategies for improved efficacy. Liver Int 44:1808\u20131831. https:\/\/doi.org\/10.1111\/liv.15953","journal-title":"Liver Int"},{"key":"5650_CR24","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2174\/1568009622666220428111327","volume":"22","author":"J Guo","year":"2022","unstructured":"Guo J, Zhao J, Xu Q, Huang D (2022) Resistance of Lenvatinib in hepatocellular carcinoma. Curr Cancer Drug Targets 22:865\u2013878. https:\/\/doi.org\/10.2174\/1568009622666220428111327","journal-title":"Curr Cancer Drug Targets"},{"key":"5650_CR25","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.62347\/UJVP4361","volume":"14","author":"G Ye","year":"2024","unstructured":"Ye G, Ye M, Jin X (2024) Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review). Am J Cancer Res 14:4113\u20134171. https:\/\/doi.org\/10.62347\/UJVP4361","journal-title":"Am J Cancer Res"},{"key":"5650_CR26","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu Y, Su Z, Tavana O, Gu W (2024) Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell 42:946\u2013967. https:\/\/doi.org\/10.1016\/j.ccell.2024.04.009","journal-title":"Cancer Cell"},{"key":"5650_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.18632\/oncotarget.28690","volume":"16","author":"JJ Miciak","year":"2025","unstructured":"Miciak JJ, Petrova L, Sajwan R, Pandya A, Deckard M, Munoz AJ, Bunz F (2025) Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells. Oncotarget 16:79\u2013100. https:\/\/doi.org\/10.18632\/oncotarget.28690","journal-title":"Oncotarget"},{"key":"5650_CR28","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41418-022-01007-x","volume":"29","author":"Y Yang","year":"2022","unstructured":"Yang Y, Yuan H, Zhao L, Guo S, Hu S, Tian M, Nie Y, Yu J, Zhou C, Niu J, Wang G, Song Y (2022) Targeting the miR-34a\/LRPPRC\/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer. Cell Death Differ 29:2177\u20132189. https:\/\/doi.org\/10.1038\/s41418-022-01007-x","journal-title":"Cell Death Differ"},{"key":"5650_CR29","doi-asserted-by":"publisher","first-page":"912","DOI":"10.4161\/cbt.6.6.4101","volume":"6","author":"F Belloc","year":"2007","unstructured":"Belloc F, Moreau-Gaudry F, Uhalde M, Cazalis L, Jeanneteau M, Lacombe F, Praloran V, Mahon FX (2007) Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther 6:912\u20139. https:\/\/doi.org\/10.4161\/cbt.6.6.4101","journal-title":"Cancer Biol Ther"},{"key":"5650_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2003057","volume":"6","author":"D Beck","year":"2013","unstructured":"Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Driessen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, Lasithiotakis K, Weide B, Eberle J, Schittek B, Schadendorf D, Garbe C, Kulms D, Meier F (2013) Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Sci Signal 6:ra7. https:\/\/doi.org\/10.1126\/scisignal.2003057","journal-title":"Sci Signal"},{"key":"5650_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/11782234241285411","author":"S Abdel-Ghany","year":"2024","unstructured":"Abdel-Ghany S, Khalid Y, Mohamed S, Mohamed G, Mohdy E, Ezzat A, Madian EF, Said OA, Abdel-Hakeem MA, Nazih M, Khoder A, Sabit H (2024) Trastuzumab induces apoptosis and cell cycle arrest in triple-negative breast cancer, suggesting repurposing potential. Breast Cancer (Auckl). https:\/\/doi.org\/10.1177\/11782234241285411","journal-title":"Breast Cancer (Auckl)"},{"key":"5650_CR32","doi-asserted-by":"publisher","first-page":"107879","DOI":"10.1016\/j.celrep.2020.107879","volume":"32","author":"S Zhang","year":"2020","unstructured":"Zhang S, Wang C, Ma B, Xu M, Xu S, Liu J, Tian Y, Fu Y, Luo Y (2020) Mutant p53 drives cancer metastasis via RCP-Mediated Hsp90alpha secretion. Cell Rep 32:107879. https:\/\/doi.org\/10.1016\/j.celrep.2020.107879","journal-title":"Cell Rep"},{"key":"5650_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M (2023) Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov 22:127\u2013144. https:\/\/doi.org\/10.1038\/s41573-022-00571-8","journal-title":"Nat Rev Drug Discov"},{"key":"5650_CR34","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1080\/15548627.2014.998892","volume":"11","author":"Y Dai","year":"2015","unstructured":"Dai Y, Grant S (2015) BCL2L11\/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance. Autophagy 11:416\u2013418. https:\/\/doi.org\/10.1080\/15548627.2014.998892","journal-title":"Autophagy"},{"key":"5650_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.lungcan.2020.12.002","volume":"151","author":"X Li","year":"2021","unstructured":"Li X, Zhang D, Li B, Zou B, Wang S, Fan B, Li W, Yu J, Wang L (2021) Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy. Lung Cancer 151:39\u201343. https:\/\/doi.org\/10.1016\/j.lungcan.2020.12.002","journal-title":"Lung Cancer"},{"key":"5650_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/science.adv4314","volume":"388","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Tian L, Huang G, Ge X, Kong F, Wang P, Xu Y, Shi Y (2025) Structural basis of BAX pore formation. Science 388:eadv4314. https:\/\/doi.org\/10.1126\/science.adv4314","journal-title":"Science"},{"key":"5650_CR37","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","volume":"14","author":"J Hu","year":"2021","unstructured":"Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, Shen J, Cai L, Cai X, Chen M (2021) Targeting mutant p53 for cancer therapy: direct and indirect strategies. J Hematol Oncol 14:157. https:\/\/doi.org\/10.1186\/s13045-021-01169-0","journal-title":"J Hematol Oncol"},{"key":"5650_CR38","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1007\/s00018-017-2575-0","volume":"74","author":"D Zhao","year":"2017","unstructured":"Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH (2017) Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci 74:4171\u20134187. https:\/\/doi.org\/10.1007\/s00018-017-2575-0","journal-title":"Cell Mol Life Sci"},{"key":"5650_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/gpbjnl\/qzaf072","author":"S Zhang","year":"2025","unstructured":"Zhang S, Chen X, Jin E, Wang A, Chen T, Zhang X, Zhu J, Dong L, Sun Y, Yu C, Zhou Y, Fan Z, Chen H, Zhai S, Sun Y, Chen Q, Xiao J, Song S, Zhang Z, Bao Y, Wang Y, Zhao W (2025) The GSA family in 2025: a broadened sharing platform for multi-omics and multimodal data. Genomics Proteomics Bioinformatics. https:\/\/doi.org\/10.1093\/gpbjnl\/qzaf072","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"5650_CR40","doi-asserted-by":"publisher","first-page":"D30","DOI":"10.1093\/nar\/gkae978","volume":"53","author":"Members C-N and Partners","year":"2025","unstructured":"Members C-N and Partners (2025) Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2025. Nucleic Acids Res 53:D30\u2013D44. https:\/\/doi.org\/10.1093\/nar\/gkae978","journal-title":"Nucleic Acids Res"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11010-026-05650-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-026-05650-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:44:58Z","timestamp":1791186298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11010-026-05650-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":40,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["5650"],"URL":"https:\/\/doi.org\/10.1007\/s11010-026-05650-7","relation":{},"ISSN":["1573-4919"],"issn-type":[{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were conducted in compliance with the protocols approved by the Animal Ethics Committee of Institutional Animal Center (IACUCFJMU 2024-Y-0376).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}